New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Gencove is raising $1,499,998.00 in new funding. Sources indicate as part of senior management President, Joseph Pickrell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gencove

Gencove’s low-pass sequencing platform is setting the new standard for high-throughput genomics research and diagnostics applications across species. Get access to whole genome information at the cost of genotyping arrays. Gencove’s imputation and analysis platform returns over 99% accurate variant calls for every sample. The components of a low-pass sequencing assay involve multiplexing large numbers of DNA samples in a single lane or run of a sequencer, sequencing them at a very low coverage (frequently starting at 0.4x), then performing genotype imputation to make genotype calls at all sites known to be polymorphic in the population. Gencove is scalable, secure, and flexible. It’s an end-to-end solution that enables your team to focus on valuable discoveries instead of the mechanics of large-scale genomic data analysis.

To learn more about Gencove, visit http://gencove.com/

Contact:
Joseph Pickrell, President
646-583-3246
joe@gencove.com
https://www.linkedin.com/in/joseph-pickrell-1b21923b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved